Evaluation of phage therapy for the treatment of Escherichia coli or Pseudomonas aeruginosa wound infections in burned patients (Phase I-II clinical trial). PHAGOBURN : Evaluation du traitement par bactériophages des plaies infectées par Escherichia coli et Pseudomonas aeruginosa chez les patients brulés (essai randomisé de phase I/II).

Drug: E. coli Phages cocktail;Drug: Standard of care : Silver Sulfadiazine;Drug: P. Aeruginosa, Phages cocktail

Inclusion Criteria:

- Man or woman

- Adult Informed consent obtained from patient or next of kin

- In-hospital patient treated for burn wounds in a burn unit

- Burn wound (grafted or not) or graft harvesting area, presenting local signs of
infection defined by SFETB criteria:

- A local or loco-regional inflammatory reaction;

- And/or an adverse and unexpected local evolution;

- And/or regarding burn wounds: presence of pus, fast spontaneous debridement and
separation, occurrence of blackish spots (necrosis or haemorrhage), unexplained
conversion from a superficial lesion to a deep one (> 48th hour);

- And/or regarding graft donor sites: presence of pus, unexplained delay in
epidermisation, bedsore;

- And/or regarding graft recipient sites: presence of pus, lysis of grafts,
necrosis of fat located under the graft.

- Burn wounds with a microbiologically documented infection, as defined by positive
surface swab, due to Escherichia coli or Pseudomonas aeruginosa whatever their
resistance profile

- Treated by povidone-iodine

Exclusion Criteria:

- Pregnant or breastfeeding woman

- Intercurrent condition requiring a treatment which may interfere with analysis
results: such as high dose of chronic corticotherapy, immunosuppressive medication,
oncologic chemotherapy

- Patient included in an interventional research protocol with therapeutic intervention
still ongoing upon inclusion time or having participated into anti-infective drug
trials during the previous month.

- Patient considered as part of a vulnerable population

- Patient for whom treatment limitation or withdrawal during study period is considered

- Allergy to Silver Sulfadiazine